Another group has recently shown that a combination of ceritinib, an ALK inhibitor, and CGM097, a MDM2 inhibitor, showed increased anti-tumour activity, and attenuated resistance to the ALK inhibitor in ALK-mutated NB cells49. Here, MDM2 is linked to neuroblastoma.